Key result
Weekly evolocumab reduces triglycerides by ~35% and prevents recurrent pancreatitis over 12 months.
Why the study?
Hypertriglyceridemia-induced pancreatitis is a common and often severe cause of acute pancreatitis that can recur despite standard lipid-lowering therapies.
Does weekly subcutaneous evolocumab 140 mg reduce triglyceride levels and prevent recurrent pancreatitis in a patient with treatment-resistant familial hypertriglyceridemia?
Case Report (n=1)
Does weekly subcutaneous evolocumab 140 mg reduce triglyceride levels and prevent recurrent pancreatitis in a patient with treatment-resistant familial hypertriglyceridemia?
Weekly off-label evolocumab 140 mg provided transient 30-40% triglyceride reductions and prevented recurrent pancreatitis over 12 months in a patient with refractory familial hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for evolocumab in refractory hypertriglyceridemia; randomized trials needed before clinical adoption.
Hypertriglyceridemia-induced pancreatitis is the third most common cause of acute pancreatitis and is often severe. We describe a case of a woman in her 60s with familial hypertriglyceridemia who suffered four pancreatitis episodes within 14 months despite treatment with fibrates, niacin, omega-3 fatty acids, statins, and icosapent ethyl. Presenting triglycerides were 39.2 to 45.7 mmol/L in three episodes and 13.5 mmol/L in the fourth. She declined plasmapheresis; volanesorsen was unavailable. Off-label evolocumab 140 mg was initiated subcutaneously. Triglycerides fell 30 to 40% within 2 to 3 days of each injection (for example, from 25.4 to 17.9 mmol/L) and rose back toward baseline by day 7. She was therefore transitioned to weekly rather than the standard biweekly dosing. Over the first 12 weeks, triglycerides ranged from 13.5 to 36.0 mmol/L (median: 19.0). At 12 months, she remained pancreatitis-free without adverse effects. Weekly evolocumab may benefit selected patients with treatment-resistant hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Javed et al. (2026) conducted a case report in Familial hypertriglyceridemia with recurrent hypertriglyceridemia-induced pancreatitis (n=1). Evolocumab was evaluated on Recurrent pancreatitis and triglyceride reduction. Weekly evolocumab lowered triglycerides by 30-40% within 2-3 days of injection and kept the patient pancreatitis-free over 12 months of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: